Researchers Identified New Cancer Immunotherapy Resistance
A study revealed that HSPA1A lactylation at lysine 108 drives immune evasion in esophageal squamous cell carcinoma.
Updated on Sept. 24, 2026 in Cancer
Scientists have discovered that the protein modification HSPA1A lactylation at lysine 108 contributes to immunotherapy resistance. This mechanism prevents the degradation of STAT1, which subsequently promotes PD-L1 expression in esophageal squamous cell carcinoma.
Why it matters
The findings explain how lactate accumulation within the tumor microenvironment facilitates immune evasion. Understanding this pathway offers a potential new target for improving the efficacy of immunotherapy treatments in patients.
The study identified that KAT5 mediates the lactylation of HSPA1A, which protects STAT1 from TRIM25-mediated ubiquitination. This stabilization leads to increased STAT1 phosphorylation and subsequent transcriptional upregulation of PD-L1.
The players
Oncogene
This is a peer-reviewed scientific journal that publishes high-quality research regarding the molecular basis of cancer.
The details
The process involves increased lactate in the tumor microenvironment enabling protein lactylation. This specific change increases HSPA1A binding affinity to STAT1, causing immune dysfunction and PD-L1 expression that shields cancer cells.
Timeline
September 24, 2026: Research findings were published in Oncogene.
The Big Picture
This study advances the current understanding of how metabolic byproducts like lactate drive immune resistance within the tumor microenvironment.
While not currently a clinical treatment, this discovery identifies a potential target for future therapies that could help make immunotherapy more effective. Patients currently undergoing treatment should continue to follow their existing protocols provided by their oncology care teams.
The takeaway
Targeting protein modification pathways like HSPA1A lactylation could eventually help overcome immunotherapy resistance in aggressive cancers. Researchers are now looking for ways to clinically modulate these specific metabolic mechanisms to improve patient outcomes.
Further reading
For more information on the evolving understanding of cancer biology, visit the Cancer section.
More information
Read the complete scientific research study for detailed molecular analysis.
Source note: This article includes information reported by Nature.
